ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance

Key Points

• ANI Pharmaceuticals issued FY 2026 guidance of EPS between $9.19 and $9.69, above the $9.10 analyst consensus, while revenue is expected to be approximately $1.1 billion, in line with estimates.
• The company’s latest quarterly results exceeded expectations, with EPS of $2.05 versus the $1.28 consensus and revenue of $237.46 million, up 20.5% year over year.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $105, although insiders sold roughly 88,000 shares worth $6.95 million over the past 90 days.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 9.190-9.690 for the period, compared to the consensus EPS estimate of 9.100. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

ANIP has been the subject of a number of research analyst reports. Zacks Research cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 14th. Guggenheim reissued a "buy" rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, May 9th. Weiss Ratings upgraded ANI Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Tuesday, June 23rd. Finally, Canaccord Genuity Group assumed coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a "hold" rating and a $91.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $105.00.

ANI Pharmaceuticals Trading Up 3.4%

NASDAQ ANIP opened at $82.63 on Friday. ANI Pharmaceuticals has a 1 year low of $67.98 and a 1 year high of $99.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The company has a market capitalization of $1.88 billion, a PE ratio of 20.92 and a beta of 0.44. The company has a fifty day moving average of $81.03 and a 200 day moving average of $79.38.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.ANI Pharmaceuticals's revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period last year, the company earned $1.70 earnings per share. Research analysts forecast that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. The trade was a 20.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 55,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $77.57, for a total value of $4,266,350.00. Following the transaction, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. This represents a 13.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 88,029 shares of company stock valued at $6,954,472 in the last ninety days. Company insiders own 8.10% of the company's stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $28,000. Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at approximately $48,000. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals in the second quarter valued at approximately $50,000. Tower Research Capital LLC TRC boosted its stake in shares of ANI Pharmaceuticals by 542.0% in the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company's stock worth $113,000 after acquiring an additional 1,458 shares during the last quarter. Finally, Maryland State Retirement & Pension System increased its position in shares of ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company's stock worth $206,000 after purchasing an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source